2011 Scrip 100: All aboard Teva's bullet train
This article was originally published in Scrip
Executive Summary
The global pharma industry is closely watching a company that has a stated aim of doubling its sales by 2015, aided by an ambitious branded product strategy and cash to spend on strategic acquisitions. This is how Teva will build its business in the post-Copaxone-protected era, CEO Shlomo Yanai tells Ashley Yeo.